Adding Dobutamine to Norepinephrine in Shock – Evidence‑Based Guideline
1. Pharmacologic Rationale
- Norepinephrine acts primarily as an α‑adrenergic vasopressor, raising systemic vascular resistance and mean arterial pressure (MAP). 2
- Its effect on cardiac output is inconsistent, often transient, and may be offset by increased afterload that unmasks underlying myocardial depression. 3
- Dobutamine is a β1‑adrenergic selective inotrope that directly enhances myocardial contractility and raises cardiac output. 2
- At low‑to‑moderate doses, dobutamine also reduces systemic and pulmonary vascular resistance while improving splanchnic and renal perfusion through the increase in cardiac output. 2
2. Guideline Recommendations
- Surviving Sepsis Campaign (SSC) recommends norepinephrine as the first‑line vasopressor; dobutamine should be added when patients exhibit persistent hypoperfusion despite adequate fluid resuscitation and norepinephrine‑derived MAP. 1
3. Indications for Adding Dobutamine
| Clinical Situation | Assessment Criteria | Evidence |
|---|---|---|
| Inadequate tissue perfusion despite MAP ≥ 65 mmHg | • Elevated lactate • Oliguria or reduced urine output • Altered mental status • Poor capillary refill | [1] |
| Low‑output state | • Central venous O₂ saturation (ScvO₂) < 70 % • High filling pressures with low measured cardiac output | [1] |
| Myocardial dysfunction | • Depressed contractility on echocardiography | [3] |
4. Practical Algorithm
- Step 1 – Initiate norepinephrine to achieve MAP ≥ 65 mmHg. 1
- Step 2 – Re‑evaluate for the above signs of ongoing hypoperfusion or low output. 1
- Step 3 – Add dobutamine (start 2–5 µg·kg⁻¹·min⁻¹, titrate up to ≈20 µg·kg⁻¹·min⁻¹) when any indication persists. 1
Rationale: Norepinephrine secures perfusion pressure, while dobutamine raises cardiac output, together optimizing oxygen delivery. 3 2
5. Monitoring & Safety
- Potential hypotension from dobutamine in patients with markedly low systemic vascular resistance; therefore norepinephrine should be established first. 2
- Both agents increase the risk of tachycardia and arrhythmias, especially at higher doses. 3
- Titrate dobutamine to physiologic endpoints (lactate clearance, urine output, ScvO₂) rather than fixed dose targets; discontinue or reduce if hypotension or arrhythmias worsen. 1
6. Alternative Inotropes
- Levosimendan may be considered in patients on chronic β‑blockade, but it often causes MAP reduction, necessitating higher norepinephrine doses. 2
- Epinephrine provides stronger β‑adrenergic stimulation than norepinephrine but carries a higher incidence of tachycardia, arrhythmias, and increased myocardial oxygen consumption. 3